Cold Chain Technologies

CCT produces passive thermal packaging — insulated shippers, phase-change material coolants, and pallet blankets — that maintain precise temperature ranges for pharmaceutical products during transit. The firm's product lines cover controlled room temperature, refrigerated, frozen, and deep-frozen profiles down to -80°C. This is engineered packaging rather than active refrigeration, relying on pre-conditioned coolants and validated container designs to hold temperature for defined durations without external power.

CCT does not move freight or manage routing. It supplies the actual containers and phase-change materials that keep products cold, along with a rental pool and conditioning network to prepare those shippers for use. Logistics providers like World Courier handle pickup, customs brokerage, and delivery. CCT sits one step upstream in the supply chain as a packaging manufacturer and rental fleet operator, selling both the physical product and the replenishment services that support it.

CCT is currently a portfolio company of Aurora Capital Partners, a Los Angeles-based private equity firm that acquired the business in May 2021 from Odyssey Investment Partners. The firm previously operated under Odyssey's ownership, during which it expanded its rental services and conditioning network.

CCT was a significant supplier of thermal packaging used in the global distribution of mRNA-based COVID-19 vaccines requiring ultra-cold storage. The firm's deep-frozen shippers and conditioning services supported the Pfizer-BioNTech vaccine rollout, which required -70°C storage during transit. This deployment stress-tested its rental model at unprecedented scale.

Yes. CCT serves clinical trial and commercial programs in over 50 countries through a combination of manufacturing sites and conditioning service centers in North America and Europe. The firm maintains strategic partnerships for regional fulfillment, allowing it to condition and deploy rental shippers near major pharma hubs globally.